These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33238573)

  • 1. Factors Associated with the Remission of Type 1 Diastolic Dysfunction after Dapagliflozin Treatment in Patients with Type 2 Diabetes.
    Braha A; Albai A; Timar R; Diaconu L; Vasiluță L; Cipu D; Timar B; Sima A
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM.
    Nada AM; Younan MA
    Ther Adv Endocrinol Metab; 2021; 12():2042018821995364. PubMed ID: 33796252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin.
    Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Metab Syndr Obes; 2019; 12():2549-2557. PubMed ID: 31819580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.
    Wilding J; Bailey C; Rigney U; Blak B; Beekman W; Emmas C
    Diabetes Ther; 2016 Dec; 7(4):695-711. PubMed ID: 27585582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy.
    González-Clemente JM; García-Castillo M; Gorgojo-Martínez JJ; Jiménez A; Llorente I; Matute E; Tejera C; Izarra A; Lecube A
    Diabetes Ther; 2022 Jul; 13(7):1281-1298. PubMed ID: 35687260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor.
    Sugiyama S; Jinnouchi H; Hieshima K; Kurinami N; Jinnouchi K
    Cureus; 2020 Feb; 12(2):e7110. PubMed ID: 32175210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.
    Tobita H; Sato S; Miyake T; Ishihara S; Kinoshita Y
    Curr Ther Res Clin Exp; 2017; 87():13-19. PubMed ID: 28912902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect and Predictive Score of Gastric Bypass and Sleeve Gastrectomy on Type 2 Diabetes Mellitus Patients with BMI < 30 kg/m(2).
    Lee WJ; Almulaifi A; Chong K; Chen SC; Tsou JJ; Ser KH; Lee YC; Chen JC
    Obes Surg; 2015 Oct; 25(10):1772-8. PubMed ID: 25676157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.
    Scheerer MF; Rist R; Proske O; Meng A; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():337-345. PubMed ID: 27822077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study.
    Lee PCH; Gu Y; Yeung MY; Fong CHY; Woo YC; Chow WS; Tan K; Lam KSL
    Diabetes Ther; 2018 Feb; 9(1):285-295. PubMed ID: 29322486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retracted: Investigating the Effects of Dapagliflozin on Cardiac Function, Inflammatory Response, and Cardiovascular Outcome in Patients with STEMI Complicated with T2DM after PCI.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9830309. PubMed ID: 37387820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan.
    Chen JF; Peng YS; Chen CS; Tseng CH; Chen PC; Lee TI; Lu YC; Yang YS; Lin CL; Hung YJ; Chen ST; Lu CH; Yang CY; Chen CC; Lee CC; Hsiao PJ; Jiang JY; Tu ST
    PeerJ; 2020; 8():e9998. PubMed ID: 33240585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.
    Pablo A; Evelyn B; Claudia F; Yanina MA
    Curr Hypertens Rev; 2021; 17(2):149-158. PubMed ID: 33238857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin.
    Yang AY; Chen HC
    Int J Clin Pharm; 2021 Aug; 43(4):1015-1023. PubMed ID: 33258006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes.
    Cha AS; Chen Y; Fazioli K; Rivara MB; Devine EB
    J Clin Endocrinol Metab; 2021 Mar; 106(4):1225-1234. PubMed ID: 33248440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
    Boorsma EM; Beusekamp JC; Ter Maaten JM; Figarska SM; Danser AHJ; van Veldhuisen DJ; van der Meer P; Heerspink HJL; Damman K; Voors AA
    Eur J Heart Fail; 2021 Jan; 23(1):68-78. PubMed ID: 33251643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
    Packer M; Butler J; Filippatos G; Zannad F; Ferreira JP; Zeller C; Brueckmann M; Jamal W; Pocock SJ; Anker SD;
    Eur J Heart Fail; 2020 Dec; 22(12):2393-2398. PubMed ID: 33251659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
    Anker SD; Butler J; Filippatos G; Shahzeb Khan M; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Seronde MF; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Eur J Heart Fail; 2020 Dec; 22(12):2383-2392. PubMed ID: 33251670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
    Ferreira JP; Verma S; Fitchett D; Ofstad AP; Lauer S; Zwiener I; George J; Wanner C; Zinman B; Inzucchi SE
    Cardiovasc Diabetol; 2020 Nov; 19(1):200. PubMed ID: 33243221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.